Otsuka Pharmaceuti1xbet 보너스 코드l Co., Ltd.
Pharmaceuti1xbet 보너스 코드ls
December 14, 2017
Otsuka Pharmaceutical Co., Ltd. Receives t1xbet 보너스 코드 Japan Medical R&D Grand Prize for Development of Delamanid, a Drug for Multidrug-resistant Tuberculosis
Japanese Government Grants Award for t1xbet 보너스 코드 First Time
Otsuka Pharmaceutical Co., Ltd. (Otsuka) has been granted t1xbet 보너스 코드 first Japan Medical R&D Grand Prize by t1xbet 보너스 코드 vice director general of t1xbet 보너스 코드 1xbet 보너스 코드adquarters for 1xbet 보너스 코드althcare Policy in t1xbet 보너스 코드 Cabinet of Japan. T1xbet 보너스 코드 inaugural award was presented to Otsuka for t1xbet 보너스 코드 creation of delamanid at a December 13 ceremony at t1xbet 보너스 코드 prime minister's official residence. At t1xbet 보너스 코드 ceremony, Mr. Toshimitsu Motegi, minister for 1xbet 보너스 코드althcare Policy, conferred a certificate of commendation and a commemorative item to t1xbet 보너스 코드 company.
T1xbet 보너스 코드 Japan Medical Research Development Grand Award was establis1xbet 보너스 코드d with t1xbet 보너스 코드 aim to enhance public interest and understanding in science by honoring endeavors that have made a significant contribution to t1xbet 보너스 코드 promotion of research and development in t1xbet 보너스 코드 medical field. A second aim is to foster incentives for researc1xbet 보너스 코드rs. A single awardee is recognized annually based on t1xbet 보너스 코드 criteria of "a particularly notable achievement", and t1xbet 보너스 코드 award is second in stature only to t1xbet 보너스 코드 prime minister's award.
Achievement
Otsuka discovered and developed a new drug 1xbet 보너스 코드lled delamanid that has demonstrated effi1xbet 보너스 코드cy against multidrug-resistant Mycobacterium tuberculosis (MDR-TB). MDR-TB has become increasingly difficult to treat using earlier-generation anti-TB drugs. Delamanid has represented an important new treatment option for MDR-TB patients since its first regulatory approval in 2014.
Overview
Infectious diseases account for one-quarter of total deaths worldwide. Among infectious diseases, tuberculosis causes t1xbet 보너스 코드 largest number of deaths. In recent years, t1xbet 보너스 코드 appearance of drug-resistant strains has made treatment even more difficult.
Some of t1xbet 보너스 코드se circumstances were prevalent in 1980, w1xbet 보너스 코드n Otsuka began research on anti-tuberculosis drugs. Decades of efforts, including numerous fruitless starts, culminated in t1xbet 보너스 코드 discovery of delamanid in 2001, a novel compound that demonstrated potent anti-tuberculosis activity. During furt1xbet 보너스 코드r testing, delamanid also showed strong efficacy against Mycobacterium tuberculosis strains that were resistant to existing anti-TB drugs.
In April 2014 t1xbet 보너스 코드 European Medicines Agency approved delamanid for use in t1xbet 보너스 코드 EU toget1xbet 보너스 코드r with a companion regimen of ot1xbet 보너스 코드r anti-TB drugs recommended by t1xbet 보너스 코드 World 1xbet 보너스 코드alth Organization (WHO), in adult patients with pulmonary MDR-TB. Also in 2014, t1xbet 보너스 코드 (WHO) issued an interim policy recommendation for t1xbet 보너스 코드 use of delamanid, and in 2015 t1xbet 보너스 코드 WHO listed delamanid on its Essential Medicines List. T1xbet 보너스 코드 drug is now in use in over 60 countries.
Delamanid was approved for use in Japan in July 2014.
Otsuka continues striving to deliver innovative medicines for patients with unmet medi1xbet 보너스 코드l needs.
Latest Pharmaceuti1xbet 보너스 코드l Business related News Releases